Biopharma Compass 2.0 wizard-driven workflows make it easy to highlight common facets of monoclonal antibody and antibody-drug conjugates (ADC) characterization, such as intact mass analysis, sequence errors, truncations, substitutions, and key PTMs such as glycosylation.
Dr. Rohan Thakur, Executive Vice President at Bruker Daltonics, commented: "The wide dynamic range of the maXis II ESI-UHR-QTOF system for large intact proteins and their low abundance isoforms has provided a unique benefit to our users trying to characterize mAbs. The exceptional functionality and convenience offered by BPC 2.0 is a result of co-developments with our biopharmaceutical customers to improve their workflow efficiency."
To learn more, please attend the technical seminar on Tuesday, January 24th, 2017 in the District Ballroom of the Mayflower Hotel in Washington, D.C. to listen to Dr. Jason Wood (Bruker) and Dr. Kristin Boggio's (Pfizer, Andover, MA) talk on 'Overcoming challenges of intact biotherapeutics characterization with ultra-high resolution mass spectrometers and the latest in automated biopharmaceutical software'.
About Bruker Corporation (NASDAQ: BRKR)
For more than 50 years, Bruker has enabled scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker's high-performance scientific research instruments and high-value analytical solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels.
In close cooperation with our customers, Bruker is enabling innovation, productivity and customer success in life science molecular research, in applied and pharma applications, in microscopy, nano-analysis and industrial applications, as well as in cell biology, preclinical imaging, clinical research, microbiology and molecular diagnostics. For more information, please visit www.bruker.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/bruker-announces-unique-and-comprehensive-workflows-for-biopharmaceutical-characterization-automated-by-biopharma-compass-20-300395501.html
SOURCE Bruker Corporation